FrancophonIA/ELRC3.0 huggingface dataset:
English: The mean residence time of the metabolites ranges from 9 to 14 hours and they are preferentially distributed to the gastro-intestinal tract, kidney, liver and adrenal glands.
Maltese: Il-ħin ta' residenza medju tal-metaboliti jvarja minn 9 sa 14-il siegħa u huma mqassma b'mod preferenzjali fil-passaġġ gastrointestinali, il-kliewi, il-fwied u l-glandoli adrenali.
English: After multiple oral doses of 2 mg spironolactone per kg (with 0.25 mg benazepril hydrochloride per kg) for 7 consecutive days, no accumulation is observed.
Maltese: Wara dożi orali multipli ta' 2 mg għal kull kg ta' spironolactone (b'0.25 mg benazepril hydrochloride għal kull kg) għal 7 ijiem konsekuttivi, l-ebda akkumulazzjoni ma ġiet osservata.
English: Benazeprilat is a highly potent and selective inhibitor of angiotensin converting enzyme (ACE), thus preventing the conversion of inactive angiotensin I to active angiotensin II.
Maltese: Benazeprilat huwa impeditur qawwi ħafna u selettiv t'enzima li tibdel angiotensin (ACE), b'hekk jiġi evitat il-konverżjoni t'angiotensin I inattiv għal angiotensin II attiv.
English: Clinical studies investigating the survival time demonstrated that the fixed combination increased the life expectancy in dogs with congestive heart failure with a 89% reduction in the relative risk of cardiac mortality assessed in dogs treated with spironolactone in combination with benazepril (as the hydrochloride) compared to dogs treated with benazepril (as hydrochloride) alone (mortality was classified as death or euthanasia due to heart failure).
Maltese: Studji kliniċi li stħarrġu lħin ta' sopravivenza wrew li l-kombinazzjoni fissa żiedet l-għomor fil-klieb b'insuffiċjenza tal-qalb konġestiva bi tnaqqis ta' 89 % fir-riskju relattiv ta' mortalità tal-qalb f'evalwazzjoni ta' klieb ittrattati bi spironolactone flimkien ma' benazepril (bħala hydrochloride) meta mqabbla ma' klieb ikkurati b'benazepril (bħala hydrochloride) waħdu (mortalità kienet ikklassifikata bħala mewt jew ewtanasja minħabba insuffiċjenza tal-qalb).
English: Interaction with other medicinal products and other forms of interactionFurosemide has been used together with this combination of benazepril (hydrochloride) and spironolactone in dogs with heart failure without any clinical evidence of adverse interactions.
Maltese: Interazzjoni ma' prodotti mediċinal oħrajn u forom oħrajn ta' interazzjoni Furosemide intuża flimkien ma' din il-kombinazzjoni ta' benazepril (hydrochloride) u spironolactone fi klieb b'insuffiċjenza tal-qalb mingħajr ebda evidenza klinika t'interazzjonijiet avversi.
English: After co-administration of spironolactone (2 mg/kg bw) and benazepril hydrochloride (0.25 mg/kg bw) the terminal plasma half-life of benazeprilat (t½) was 18 hours.
Maltese: Wara l-għoti konġunt ta' spironolactone (2 mg/kg piż tal-ġisem) u benazepril hydrochloride (0.25 mg/kg piż tal-ġisem) il-half-life terminali ta' benazeprilat fil-plażma(t½) kien ta' 18-il siegħa.
English: Furosemide has been used together with this combination of benazepril hydrochloride and spironolactone in dogs with heart failure without any clinical evidence of adverse interactions.
Maltese: Furosemide intuża flimkien ma' din il-kombinazzjoni ta' benazepril hydrochloride u spironolactone fi klieb b'insuffiċjenza tal-qalb mingħajr ebda evidenza klinika t'interazzjonijiet avversi.
English: A dose related but moderate compensatory physiological hypertrophy of zona glomerulosa of the adrenal glands was also observed at doses of 3 times and greater of the recommended dose.
Maltese: Ipertrofija fiżjoloġika kompensatorja moderata taż-żona glomerulosa tal-glandoli adrenali ġiet osservata f'dożi 3 darbiet u aktar tad-doża rakkomandata.
English: Bodyweight (kg) of dog
Maltese: Piż tal-ġisem (kg) tal-klieb
English: PACKAGE LEAFLET
Maltese: FIL-PAKETT
English: The concomitant administration of this veterinary medicinal product with other potassium-sparing treatments (such as ß-blockers, calcium channels blockers, angiotensin receptor blockers) may potentially lead to hyperkalaemia (see section 4.5).
Maltese: L-għoti flimkien ta' dan il-prodott mediċinali veterinarju ma' trattamenti li jrażżnu l-potassju (bħal imblokkaturi β, imblokkaturi tal-kanali tal-kalċju, imblokkaturi tar-riċetturi t'angiotensin) jistgħu potenzjalment iwasslu għal iperkalemija (ara sezzjoni 4.5).
English: Following oral administration of 2 to 4 mg/kg, absorption increases linearly over the range.
Maltese: Wara amministrazzjoni orali ta' 2 sa 4 mg/kg, l-assorbiment jiżdied b'mod lineari fuq il-medda.
English: Do not use during pregnancy and lactation.Embryotoxic effects (foetal urinary tract malformation) were seen in trials of benazepril (as hydrochloride) with laboratory animals (rats) at maternally nontoxic doses.
Maltese: Effetti embrijotossiċi (malformazzjoni fl-apparat awrinarju tal-fetu) dehru fi provi ta' benazepril ma' annimali tal-laboratorju (firien) f' dożi maternali mhux tossiċi.
English: INDICATION
Maltese: MANIFATTURI
English: Pregnancy and lactation
Maltese: ANNESS I KARATTERISTIĊI
English: The tablets are packed bottles of 30 tablets or 90 tablets, and each bottle is presented in an outer cardboard box.
Maltese: Il-pilloli huma ppakkjati fi fliexken ta' 30 pillola jew 90 pillola, u kull flixkun huwa ppreżentat f'kaxxa talkartun ta' barra.
English: Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.
Maltese: Tużax f'każijiet ta' falliment fl-isforz kardijaku minħabba stenożi aortika jew pulmonari.
English: Cardalis 2.5 mg/20 mg chewable tablets for dogs Cardalis 5 mg/40 mg chewable tablets for dogs Cardalis 10 mg/80 mg chewable tablets for dogs benazepril HCl/spironolactone
Maltese: VETERINARJU Cardalis 2.5 mg/20 mg pilloli li tomgħod għal klieb Cardalis 5 mg/40 mg pilloli li tomgħod għal klieb Cardalis 10 mg/80 mg pilloli li tomgħod għal klieb benazepril HCl/spironolactone
English: After multiple oral doses of 0.25 mg benazepril hydrochloride per kg (with 2 mg spironolactone per kg) for 7 consecutive days, a peak benazeprilat concentration (Cmax of 52.4 ng/ml) is achieved with a Tmax of 1.4 h.
Maltese: Wara dożi orali multipli ta' 0.25 mg benzaperil hydrochloride għal kull kg (b'2 mg spironolactone għal kull kg) għal 7 ijiem konsekuttivi, l-ogħla konċentrazzjoni ta' benazeprilat (Cmax ta' 52.4 ng/ml) tinkiseb b'Tmax ta' 1.4 sigħat.
English: QUANTITY OF THE ACTIVE SUBSTANCE(S)
Maltese: DIKJARAZZJONI TAS-SUSTANZA(I)
English: Benazepril and benazeprilat are extensively bound to plasma proteins, and in tissues are found mainly in the liver and kidney.
Maltese: Benazepril u benazeprilat huma estensivament marbuta mal-proteini tal-plażma, u fittessuti jinstabu prinċipalment fil-fwied u l-kliewi.
English: This hypertrophy does not seem to be linked to any pathology and was observed to be reversible upon discontinuation of the treatment.
Maltese: Din lipertrofija ma tidhirx li hija marbuta ma' kwalunkwe patoloġija u kienet osservata li hija riversibbli mattwaqqif tat-trattament.
English: Benazepril and benazeprilat are rapidly distributed, mainly in liver and kidney.
Maltese: Benazepril u benazeprilat huma distribwiti malajr, prinċipalment fil-fwied u kliewi.
English: Cardalis 2.5 mg/20 mg chewable tablets for dogs Cardalis 5 mg/40 mg chewable tablets for dogs Cardalis 10 mg/80 mg chewable tablets for dogs
Maltese: VETERINARJU Cardalis 2.5 mg/20 mg pilloli li tomgħod għal klieb Cardalis 5 mg/40 mg pilloli li tomgħod għal klieb Cardalis 10 mg/80 mg pilloli li tomgħod għal klieb
English: The tablets contain beef flavouring to improve palatability, and in a field study conducted in dogs with chronic degenerative valvular disease the tablets were voluntarily and fully consumed 92% of the time when offered either with or without food.
Maltese: Il-pilloli fihom togħma ta' ċanga biex titjieb il-palatibilità, u fi studju fil-kamp li sar fuq klieb b'mard valvulari deġenerattiv, il-pilloli ttieħdu b'mod volontarju u ġew konsumati f'92 % tal-ħin meta ngħataw bi jew mingħajr ikel.
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Bottle of 30 tablets
Maltese: DAQS TAL-PAKKETT 30 pillola
English: The concomitant administration of this veterinary medicinal product with other anti-hypertensive agents (e.g. calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may potentially lead to additive hypotensive effects.
Maltese: L-għoti fl-istess ħin ta' dan il-prodott mediċinali veterinarju ma' sustanzi ta' kontra l-pressjoni għolja (eż. imblokkaturi tal-kanali tal-kalċju, imblokkaturi β jew dijuretiċi), anestetiċi jew sedattivi jista' potenzjalment iwassal għal effetti addittivi.
English: Pharmacotherapeutic group: Agents acting on the renin-angiotensin system, ACE inhibitors, combinations.
Maltese: Trattament sintomatiku, eż, it-terapija fluwida, għandha tiġi pprovduta wkoll.
English: EXPIRY DATE
Maltese: DATA TA' REVIŻJONI TAT-TEST
English: Benazeprilat concentrations decline biphasically: the initial fast phase represents elimination of free drug, while the terminal phase reflects the release of benazeprilat that was bound to ACE, mainly in the tissues.
Maltese: Il-konċentrazzjonijiet ta' benazeprilat jonqsu b'mod bifażiku: il-fażi inizjali mgħaġġla tirrappreżenta eliminazzjoni ta' mediċina libera, filwaqt li l-fażi terminali tirrifletti r-rilaxx ta' benazeprilat li kien marbut m'ACE, prinċipalment fit-tessuti.
English: After administration of up to 10 times the recommended dose (2.5 mg/kg bw benazepril hydrochloride, 20 mg/kg bw spironolactone) to healthy dogs, dose dependant adverse effects were noted (see section 4.6).
Maltese: Wara l-għoti sa 10 darbiet id-doża rakkomandata (2.5 mg/kg piż tal-ġisem għal benazepril hydrochloride u 20 mg/kg piż tal-ġisem għal spironolactone) lil klieb f'saħħithom, effetti avversi dipendenti fuq id-doża kienu osservati (ara sezzjoni 4.6).
English: Strength and number of tablets to be administered: Cardalis 2.5 mg/20 mg chewable tablets
Maltese: Qawwa u n-numru ta' pilloli li jkunu amministrati Pilloli li tomgħod ta' Cardalis 2.5 mg/20 mg
English: Each chewable tablet contains:
Maltese: Data tal-aħħar tiġdid:
English: The product causes a long-lasting inhibition of plasma ACE activity in dogs, with more than 95% inhibition at peak effect and significant activity (>80%) persisting 24 hours after dosing.
Maltese: Il-prodott jikkawża inibizzjoni fit-tul tal-attivita t'ACE fil-plażma fil-klieb, b'aktar minn 95 % impediment waqt l-aktar effett għoli u attività sinifikanti (> 80%) li tippersisti għal 24 siegħa wara d-dożaġġ.
English: Cardalis 2.5 mg/20 mg chewable tablets for dogs Benazepril hydrochloride 2.5 mg, spironolactone 20 mg Cardalis 5 mg/40 mg chewable tablets for dogs Benazepril hydrochloride 5 mg, spironolactone 40 mg Cardalis 10 mg/80 mg chewable tablets for dogs Benazepril hydrochloride 10 mg, spironolactone 80 mg
Maltese: FULJETT TA' TAGĦRIF Cardalis 2.5 mg/20 mg pilloli li tomgħod għal klieb Cardalis 5 mg/40 mg pilloli li tomgħod għal klieb Cardalis 10 mg/80 mg pilloli li tomgħod għal klieb
English: The concomitant administration of this veterinary medicinal product with other potassium-sparing treatments (such as ß-blockers, calcium channels blockers, angiotensin receptor blockers) may potentially lead to hyperkalaemia (see section "Special precautions for use in animals").
Maltese: L-għoti konġunt ta' dan il-prodott mediċinali veterinarju ma' trattamenti oħra li jirrestrinġu l-potassju (bħal imblokkaturi β, imblokkaturi tal-kanali tal-kalċju, imblokkaturi tar-riċetturi ta' angiotensin, eċċ) tista' potenzjalment twassal għal iperkalemija (ara sezzjoni "Prekawzjonijiet speċjali għall-użu fl-annimali").
English: Daily overdoses to healthy dogs, i.e. 6 times (1.5 mg/kg bw benazepril hydrochloride, 12 mg/kg bw spironolactone) and 10 times (2.5 mg/kg bw benazepril hydrochloride, 20 mg/kg bw spironolactone) the recommended dose, led to a slight dose related decrease in red cell mass.
Maltese: Dożi eċċessivi ta' kuljum fuq klieb f'saħħithom, jiġifieri, 6 darbiet (1.5 mg/kg piż tal-ġisem għal benazepril hydrochloride u 12 mg/kg piż tal-ġisem għal spironolactone) u 10 darbiet (2.5 mg/kg piż talġisem għal benazepril hydrochloride u 20 mg/kg piż tal-ġisem għal spironolactone) id-doża rakkomandata, wassal għal tnaqqis żgħir fil-massa taċ-ċelluli ħomor li kien xi ftit marbut mad-doża.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box of 1 bottle of 30 tablets
Maltese: TAGĦRIF LI GĦANDU JIDHER FUQ IL-PAKKETT TA' BARRA Kaxxa tal-kartun ta' flixkun 1 ta' 30 pillola
English: The concomitant administration of the product with other anti-hypertensive agents (e.g. calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may potentially lead to additive hypotensive effects.
Maltese: L-għoti fl-istess ħin ta' dan il-prodott ma' sustanzi ta' kontra l-pressjoni għolja (eż. imblokkaturi tal-kanali tal-kalċju, imblokkaturi β jew dijuretiċi), anestetiċi jew sedattivi jista' potenzjalment iwassal għal effetti addittivi.
English: After the oral administration of radiolabelled spironolactone to the dog, 70% of the dose is recovered in faeces and 20% in the urine.
Maltese: Wara l-għoti orali ta' spironolactone radjutikkettat lill-kelb, 70 % tad-doża ġiet rkuprata mill-ippurgar u 20 % fl-awrina.
English: It is therefore recommended to induce vomiting, and then carry out gastric lavage (depending on the risk assessment) and monitor electrolytes.
Maltese: Għalhekk huwa rakkomandat li tqanqal ir-remettar, u mbagħad wettaq ħasil gastriku skont l-istima tar-riskju) u mmonitorja l-elettroliti.
English: After oral administration of benazepril hydrochloride, peak levels of benazepril are attained rapidly and decline quickly as the drug is partially metabolized by liver enzymes to benazeprilat.
Maltese: Wara għoti orali ta' benazepril hydrochloride, l-ogħla livelli ta' benazepril jintlaħqu malajr u jinżlu malajr peress li l-mediċina hija parzjalment metabolizzata minn enzimi tal-fwied għal benazeprilat.
English: However, regular monitoring of renal function and serum potassium levels is recommended in dogs with renal impairment, as they may have an increased risk of hyperkalaemia during treatment with this product.
Maltese: Madankollu, il-monitoraġġ regolari tal-funzjoni renali u l-livelli ta' potassju fis-serum huwa rakkomandat fi klieb b'indeboliment tal-kliewi, li jista' jkollhom riskju akbar ta' iperkalemja waqt it-trattament b'dan il-prodott.
English: The tablets can be divided into equal halves.
Maltese: Il-pilloli jistgħu jinqasmu f'nofsijiet indaqs.
English: Ustekinumab attaches to two cytokines (messenger molecules) in the immune system called interleukin 12 and interleukin 23.
Maltese: Lustekinumab teħel ma' żewġ ċitokini (molekuli messaġġiera) fis-sistema immunitarja msejħa interleukin-12 u interleukin-23.
English: The active substance in Stelara, ustekinumab, is a monoclonal antibody.
Maltese: Is-sustanza attiva fi Stelara, l-ustekinumab, hija antikorp monoklonali.
English: Why is Stelara approved?
Maltese: Għaliex ġie approvat Stelara?
English: Other information about Stelara
Maltese: Informazzjoni oħra dwar Stelara
English: This is a summary of the European public assessment report (EPAR) for Stelara.
Maltese: Dan id-dokument huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Stelara.
English: Stelara contains the active substance ustekinumab.
Maltese: Stelara fih is-sustanza attiva ustekinumab.
English: In the second study the figures were 56% for Stelara and 29% for placebo.
Maltese: Fit-tieni studju ċ-ċifri kienu 56% għal Stelara u 29% għal plaċebo.
English: Crohn's disease
Maltese: Marda ta' Crohn
English: EPAR summary for the public
Maltese: Sommarju tal-EPAR għall-pubbliku ustekinumab
English: In the first study, around 42% of those given Stelara 45 mg and 50% of those given 90 mg responded, compared with around 23% of those given placebo.
Maltese: Fl-ewwel studju, madwar 42% ta' dawk li ngħataw Stelara 45 mg u 50% ta' dawk li ngħataw 90 mg kellhom rispons meta mqabbla ma' 23% ta' dawk li ngħataw plaċebo.
English: In around 69% of children (25 out of 36) who received Stelara responded, compared with 5% of patients receiving placebo (2 out of 37).
Maltese: Madwar 69% tat-tfal (25 minn 36) li ngħataw Stelara kellhom rispons, meta mqabbla ma' 5% tal-pazjenti li ngħataw plaċebo (2 minn 37).
English: Stelara is available as a solution for injection (45 and 90 mg) in vials or prefilled syringes and as a concentrate (130 mg) to make a solution for infusion (drip) into a vein.
Maltese: Stelara jiġi bħala soluzzjoni għall-injezzjoni (45 u 90 mg) f'kunjetti jew siringi mimlija lesti u bħala konċentrat (130 mg) biex isir f'soluzzjoni għall-infużjoni (dripp) fil-vina.
English: In the treatment of active psoriatic arthritis, Stelara was compared with placebo in two main studies involving a total of 927 adults with the condition who did not have an adequate response with previous treatments.
Maltese: Fil-kura tal-artrite psorjatika attiva, Stelara tqabbel ma' plaċebo f'żewġ studji ewlenin li involvew total ta' 927 adult b'din il-kundizzjoni u li ma kellhomx rispons adegwat b'kuri preċedenti.
English: The full EPAR for Stelara can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: L-EPAR sħiħ għal Stelara jista' jiġi kkonsultat fis-sit elettronika tal-Aġenzija ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports Għal aktar informazzjoni rigward ilkura bi Stelara, aqra l-fuljett ta' tagħrif (parti wkoll mill-EPAR) jew ikkuntattja lit-tabib jew lill-ispiżjar tiegħek.
English: • active psoriatic arthritis (inflammation of the joints associated with psoriasis) in adults, when the condition has not responded well enough to other treatments called disease-modifying antirheumatic drugs' (DMARDs).
Maltese: • l-artrite psorjatika attiva (infjammazzjoni fil-ġogi marbuta mal-psorijażi) fl-adulti, meta lkundizzjoni ma kellhiex rispons tajjeb biżżejjed għal kuri oħra li jissejħu 'mediċini antirewmatiċi li jimmodifikaw il-marda' (DMARDs).
English: After 44 weeks of starting treatment by injection under the skin, 53% of patients on Stelara every 8 weeks and 49% of patients on Stelara every 12 weeks had a significant reduction in symptoms of Crohn's disease, compared with 36% of patients on placebo.
Maltese: Wara 44 ġimgħa mill-bidu tal-kura permezz ta' injezzjoni taħt il-ġilda, 53% tal-pazjenti li ħadu Stelara kull 8 ġimgħat u 49% tal-pazjenti li ħadu Stelara kull 12-il ġimgħa kellhom tnaqqis sinifikanti fis-sintomi tal-marda ta' Crohn, meta mqabbla ma' 36% tal-pazjenti li ħadu plaċebo.
English: Plaque psoriasis
Maltese: Psorijażi bil-qoxra
English: An additional study involved 110 children with moderate to severe plaque psoriasis aged between 12 and 18 years.
Maltese: Studju ieħor ħares ukoll lejn 110 tifel u tifla li kienu jbatu minn psorijażi bil-qoxra minn moderata sa severa li kellhom bejn 12 u 18-il sena.
English: In the treatment of moderate to severe plaque psoriasis, Stelara has been compared with placebo (a dummy treatment) in two main studies involving a total of 1,996 adults with the condition.
Maltese: Fil-kura ta' psorijażi bil-qoxra minn moderata sa severa, Stelara tqabbel ma' plaċebo (kura finta) f'żewġ studji ewlenin li involvew total ta' 1,996 adult b'din il-kundizzjoni.
English: What are the risks associated with Stelara?
Maltese: X'inhuma r-riskji assoċjati ma' Stelara?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Stelara on 16 January 2009.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Stelara valida fl-Unjoni Ewropea kollha fis-16 ta' Jannar 2009.
English: The most serious side effect reported with Stelara is serious hypersensitivity (allergic reaction).
Maltese: L-effett sekondarju l-aktar serju li ġie rrapportat bi Stelara kien ipersensittività serja (reazzjoni allerġika).
English: In the treatment of Crohn's disease, Stelara (concentrate for infusion) was compared with placebo in two main studies involving 1,369 patients with moderately to severely active disease.
Maltese: Fil-kura tal-marda ta' Crohn, Stelara (konċentrat għall-infużjoni) tqabbel ma' plaċebo f'żewġ studji ewlenin li involvew 1,396 pazjenti b'marda attiva minn moderata sa severa.
English: Stelara may be used alone or combined with methotrexate (a DMARD);
Maltese: Stelara jista' jintuża waħdu jew flimkien mal-metrotressat (DMARD);
English: Stelara was more effective than placebo at improving the symptoms of plaque psoriasis.
Maltese: Stelara kien aktar effettiv mill-plaċebo fit-titjib tas-sintomi tal-psorijażi bil-qoxra.
English: The CHMP considered that studies had shown that Stelara was effective in the treatment of adults and children over 12 years of age with moderate to severe plaque psoriasis.
Maltese: Is-CHMP kkunsidra li l-istudji wrew li Stelara kien effettiv fil-kura ta' adulti u tfal ta' aktar minn 12-il sena li jbatu minn psorijażi bil-qoxra minn moderata sa severa.
English: A monoclonal antibody is a type of protein that has been designed to recognise and attach to a specific structure (called an antigen) in the body.
Maltese: Antikorp monoklonali huwa tip ta' proteina li ġie ddisinjat sabiex jagħraf u jeħel ma' struttura speċifika (imsejħa antiġen) fil-ġisem.
English: The most common side effects with Stelara (seen in more than 5% of patients during clinical trials) are headache and nasopharyngitis (inflammation of the nose and throat).
Maltese: L-effetti sekondarji l-aktar komuni bi Stelara (li dehru f'aktar minn 5 % tal-pazjenti waqt provi kliniċi) huma wġigħ ta' ras u farinġite nażali (infjammazzjoni tal-imnieħer u l-gerżuma).
English: Patients weighing over 100 kg should be given Stelara in 90-mg doses for psoriasis, and this should also be considered for psoriatic arthritis.
Maltese: Pazjenti li jiżnu aktar minn 100 kg għandhom jingħataw Stelara f'dożi ta' 90 mg għal psorijażi u dan għandu jitqies ukoll għall-artrite psorjatika.
English: PUVA is a type of treatment where the patient receives a medicine containing a compound called a ‘psoralen' before being exposed to ultraviolet light.
Maltese: Il-PUVA huwa tip ta' kura fejn il-pazjent jirċievi mediċina li fiha kompost imsejjaħ ‘psoralen' qabel ma jiġi espost għal dawl ultravjola.
English: • moderate to severe plaque psoriasis (a disease causing red, scaly patches on the skin).
Maltese: • psorijażi bil-qoxra minn moderata sa severa (marda li tikkawża rqajja' ħomor bil-qxur fuq il-ġilda).
English: In Crohn's disease, the effects of Stelara in reducing symptoms in patients in whom other treatments had failed or who could not receive them were considered important, also given the unmet medical need of these patients.
Maltese: Fil-każ tal-marda ta' Crohn, l-effetti ta' Stelara fit-tnaqqis tas-sintomi f'pazjenti li fuqhom kuri oħrajn ma rnexxewx jew li ma setgħux jirċevuhom kienu kkunsidrati importanti, anke wkoll minħabba l-bżonn mediku mhux sodisfat ta' dawn il-pazjenti.
English: The company subsequently provided the longer-term results of the studies (after 5 years of treatment), and the results of a study comparing Stelara with etanercept (another medicine for psoriasis).
Maltese: Sussegwentement il-kumpanija pprovdiet ir-riżultati fuq terminu itwal tal-istudji (wara 5 snin ta' kura), u r-riżultati ta' studju li jqabbel Stelara ma' etanercept (mediċina oħra għall-psorijażi).
English: For adults the usual dose is 45 mg, whereas the dose in children depends on bodyweight.
Maltese: Għalladulti d-doża regolari hija 45 mg, filwaqt li d-doża għat-tfal tiddependi mill-piż tal-ġisem.
English: It is used in adults and children above the age of 12 years whose condition has not responded to or who cannot use other systemic (whole-body) psoriasis treatments, such as ciclosporin, methotrexate or PUVA (psoralen ultraviolet A).
Maltese: Jintuża fuq adulti u tfal ta' aktar minn 12-il sena li l-kundizzjoni tagħhom ma kellhiex rispons għal kuri sistemiċi (fuq il-ġisem kollu) oħrajn għall-psorijażi, bħaċ-ċiklosporina, il-metrotressat jew ilPUVA (psoralen ultravjola-A) jew li ma jistgħux jużawhom.